NCT07359820
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT07359820 |
| Title | A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement (ReFocus202) |
| Acronym | ReFocus202 |
| Recruitment | Not yet recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | Elevar Therapeutics |
| Indications | |
| Therapies | |
| Age Groups: | senior |
| Covered Countries | USA | GBR | FRA | ESP |
CKB BOOST